Home > Publications Database > The FGFR inhibitor Rogaratinib reduces microglia reactivity and synaptic loss in TBI. > print

001     273922
005     20241215000113.0
024 7 _ |a 10.3389/fimmu.2024.1443940
|2 doi
024 7 _ |a pmid:39635532
|2 pmid
024 7 _ |a pmc:PMC11614719
|2 pmc
024 7 _ |a altmetric:170930407
|2 altmetric
037 _ _ |a DZNE-2024-01396
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Rehman, Rida
|b 0
245 _ _ |a The FGFR inhibitor Rogaratinib reduces microglia reactivity and synaptic loss in TBI.
260 _ _ |a Lausanne
|c 2024
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1733823757_31710
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Traumatic brain injury (TBI) induces an acute reactive state of microglia, which contribute to secondary injury processes through phagocytic activity and release of cytokines. Several receptor tyrosine kinases (RTK) are activated in microglia upon TBI, and their blockade may reduce the acute inflammation and decrease the secondary loss of neurons; thus, RTKs are potential therapeutic targets. We have previously demonstrated that several members of the Fibroblast Growth Factor Receptor (FGFR) family are transiently phosporylated upon TBI; the availability for drug repurposing of FGFR inhibitors makes worthwhile the elucidation of the role of FGFR in the acute phases of the response to TBI and the effect of FGFR inhibition.A closed, blunt, weight-drop mild TBI protocol was employed. The pan-FGFR inhibitor Rogaratinib was administered to mice 30min after the TBI and daily up to 7 days post injury. Phosphor-RTK Arrays and proteomic antibody arrays were used to determine target engagement and large-scale impact of the FGFR inhibitor. pFGFR1 and pFGFR3 immunostaining were employed for validation. As outcome parameters of the TBI injury immunostainings for NeuN, VGLUT1, VGAT at 7dpi were considered.Inhibition of FGFR during TBI restricted phosphorylation of FGFR1, FGFR3, FGFR4 and ErbB4. Phosphorylation of FGFR1 and FGFR3 during TBI was traced back to Iba1+ microglia. Rogaratinib substantially dowregulated the proteomic signature of the neuroimmunological response to trauma, including the expression of CD40L, CXCR3, CCL4, CCR4, ILR6, MMP3 and OPG. Prolonged Rogaratinib treatment reduced neuronal loss upon TBI and prevented the loss of excitatory (vGLUT+) synapses.The FGFR family is involved in the early induction of reactive microglia in TBI. FGFR inhibition selectively prevented FGFR phosphorylation in the microglia, dampened the overall neuroimmunological response and enhanced the preservation of neuronal and synaptic integrity. Thus, FGFR inhibitors may be relevant targets for drug repurposing aimed at modulating microglial reactivity in TBI.
536 _ _ |a 352 - Disease Mechanisms (POF4-352)
|0 G:(DE-HGF)POF4-352
|c POF4-352
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a proteomics
|2 Other
650 _ 7 |a reactive microglia
|2 Other
650 _ 7 |a receptor tyrosine kinase
|2 Other
650 _ 7 |a synapses
|2 Other
650 _ 7 |a traumatic brain injury
|2 Other
650 _ 7 |a Receptor, Fibroblast Growth Factor, Type 1
|0 EC 2.7.10.1
|2 NLM Chemicals
650 _ 7 |a Protein Kinase Inhibitors
|2 NLM Chemicals
650 _ 2 |a Animals
|2 MeSH
650 _ 2 |a Microglia: drug effects
|2 MeSH
650 _ 2 |a Microglia: metabolism
|2 MeSH
650 _ 2 |a Brain Injuries, Traumatic: drug therapy
|2 MeSH
650 _ 2 |a Brain Injuries, Traumatic: metabolism
|2 MeSH
650 _ 2 |a Brain Injuries, Traumatic: immunology
|2 MeSH
650 _ 2 |a Mice
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Synapses: drug effects
|2 MeSH
650 _ 2 |a Synapses: metabolism
|2 MeSH
650 _ 2 |a Mice, Inbred C57BL
|2 MeSH
650 _ 2 |a Phosphorylation: drug effects
|2 MeSH
650 _ 2 |a Disease Models, Animal
|2 MeSH
650 _ 2 |a Receptor, Fibroblast Growth Factor, Type 1: antagonists & inhibitors
|2 MeSH
650 _ 2 |a Receptor, Fibroblast Growth Factor, Type 1: metabolism
|2 MeSH
650 _ 2 |a Protein Kinase Inhibitors: pharmacology
|2 MeSH
650 _ 2 |a Protein Kinase Inhibitors: therapeutic use
|2 MeSH
700 1 _ |a Froehlich, Albrecht
|b 1
700 1 _ |a Olde Heuvel, Florian
|b 2
700 1 _ |a Elsayed, Lobna
|b 3
700 1 _ |a Boeckers, Tobias
|0 P:(DE-2719)2812855
|b 4
|u dzne
700 1 _ |a Huber-Lang, Markus
|b 5
700 1 _ |a Morganti-Kossmann, Cristina
|b 6
700 1 _ |a Roselli, Francesco
|0 P:(DE-2719)2812851
|b 7
|e Last author
|u dzne
773 _ _ |a 10.3389/fimmu.2024.1443940
|g Vol. 15, p. 1443940
|0 PERI:(DE-600)2606827-8
|p 1443940
|t Frontiers in immunology
|v 15
|y 2024
|x 1664-3224
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/273922/files/DZNE-2024-01396.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/273922/files/DZNE-2024-01396.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:273922
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2812855
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2812851
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-352
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-26
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT IMMUNOL : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-05-11T10:28:02Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-05-11T10:28:02Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-26
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-26
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Anonymous peer review
|d 2021-05-11T10:28:02Z
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2023-10-26
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FRONT IMMUNOL : 2022
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-26
920 1 _ |0 I:(DE-2719)1910001
|k AG Roselli
|l Metabolic Changes in Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1910002
|k AG Böckers
|l Translational Protein Biochemistry
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1910001
980 _ _ |a I:(DE-2719)1910002
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21